Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02973399 · ClinicalTrials.gov registry record · Phase 1
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
A Phase 1 study, sponsored by Esanex.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02973399: Clinical Trial Phase 1 study, sponsored by Esanex.
NCT02973399 is a Phase 1 study that was terminated before completion, run by Esanex. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02973399, a Phase 1 study, was terminated before completion, sponsored by Esanex.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the addition of SNX-5422 to an established dose of ibrutinib will provide clinical response in subjects who have residual disease, but have not progressed on ibrutinib after 18 months of monotherapy, and/or prevents or delays disease progression of subjects with CLL.
Primary Outcome
Proportion of subjects obtaining a complete response at the end of 6 SNX-5422 treatment cycles
Interventions
- DRUG SNX-5422 plus ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-02-07 |
| Est. Completion | 2019-02-04 |
| Phase | Phase 1 |
Why NCT02973399 stopped before completion
NCT02973399 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which SNX-5422 plus ibrutinib is the first listed.
NCT02973399 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02973399 about?
NCT02973399 is a clinical study titled "Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL". SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the addition of SNX-5422 to an establi...
What is the current status of trial NCT02973399?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-02-07. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT02973399?
The interventions under investigation include: SNX-5422 plus ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02973399?
This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02973399's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI